2023 World Conference on Lung Cancer (Posters)-EP12.02. The Response to First-line Therapies in Stage IV RET Fusion-Positive Non-small Cell Lung Cancer: a Multi-center Retrospective Study in China

EP12.02. The Response to First-line Therapies in Stage IV RET Fusion-Positive Non-small Cell Lung Cancer: a Multi-center Retrospective Study in China - PDF(Abstract)

Back to course

Pdf Summary

A retrospective study conducted in China evaluated the clinical efficacy of first-line therapies for stage IV non-small cell lung cancer (NSCLC) patients with RET fusions. The study included patients from six cancer centers between May 2017 and October 2022 who received either RET tyrosine kinase inhibitors (RET-TKI), chemotherapy, or combination therapies as their first-line treatment. The study found that patients who received RET-TKI displayed the best progress-free survival (PFS), with a median PFS of 16.92 months. Combination therapy had a median PFS of 8.7 months, while chemotherapy had the worst PFS at 5.55 months. The objective response rate (ORR) was 71.4% for RET-TKI, 17.8% for combination therapy, and 6.7% for chemotherapy. Patients who couldn't afford RET-TKI treatment had better PFS with combination therapy that included Bevacizumab (BC) or BC and immune checkpoint inhibitor (IBC) compared to chemotherapy alone. The study also observed a longer median PFS in the IBC group compared to the BC or immune checkpoint inhibitor (IC) group. The most frequent adverse events in patients who received RET-TKI were pneumonia and transaminase increase, while IBC treatment had the highest frequency of hematological toxicity and vomiting. The study concluded that RET-TKI is the best first-line therapy for RET fusion-positive NSCLC, and IBC may be a preferable option for patients who can't afford RET-TKI. BC offered better survival outcomes compared to chemotherapy.

Asset Subtitle

aiqin Gao

Meta Tag

Speaker aiqin Gao

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

retrospective study

China

clinical efficacy

first-line therapies

stage IV NSCLC

RET fusions

RET-TKI

chemotherapy

combination therapy

progress-free survival